imatinib

(redirected from Gleevac)
Also found in: Medical.

i·mat·i·nib

 (ĭ-măt′ə-nĭb)
n.
A tyrosine kinase inhibitor, C29H31N7O, used in its mesylate form to treat certain types of leukemia and various other diseases.
References in periodicals archive ?
director, Knight Cancer Institute at Oregon Health & Science University, on Gleevac, an anti-cancer drug targeting leukemia; and,
Gleevac, also called imatinib mesylate, is approved by the FDA to treat some types of leukemia and other forms of cancer.
5 Gleevac targets BCR-ABL gene product, characteristic of Chronic Myeloid Leukaemia and is also effective in blocking the "Kinase Pocket" of the platelet derived growth factor receptor and C-Kit.
The recent patent clashes in the Indian courts on two anti-cancer drugs Gleevac and Erlontinib highlights the issue.
He was put on anti-cancer drug Gleevac and warned against starting a family.
The Swiss pharmaceutical company Novartis, which makes an anti-leukemia drug called Gleevac specifically targeting a particular form of cancer, has tested the new law, by seeking to overturn a local ruling that would have prevented Novartis from extending its patent over Gleevac, at a time when Indian generic drug makers want to enter the market.
In the 1980s, some pharmaceutical companies focused on the development of such drugs, including Gleevac, in order to reduce side effects and increase effectiveness.
Another recurrence 18 months later led physicians to try Gleevac therapy, a tyrosine kinase inhibitor, because the tumor was positive for "c-kit" oncogene (CD117).